Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunogenicity of a Commercial Batch of the Japanese Encephalitis Vaccine IC51 up to Twenty-four Months Post Filling. An Open-label, Multicenter, Phase 3 Study

NCT00776230 is registered in ClinicalTrials.gov with Valneva Austria GmbH as lead sponsor.

NCT NCT00776230
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00776230 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunogenicity of a Commercial Batch of the Japanese Encephalitis Vaccine IC51 up to Twenty-four Months Post Filling. An Open-label, Multicenter, Phase 3 Study
Lead sponsor
Valneva Austria GmbH
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2008
Completion date
June 30, 2010
Enrollment
304 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

japanese encephalitis